Mi Ri Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mi Ri Park has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Seung-Tae Lee
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
7 shared publications - Saeam Shin
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
6 shared publications - Jong Rak Choi
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Yu Jin Park
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Dongju Won
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Hyeonah Lee
Division of Zoonotic and Vector Borne Disease Research, Center for Infectious Disease Research, Korea National Institute of Health, Cheongju, Korea
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Chimerism Analysis Through Shallow Whole-Genome Sequencing and Single-Nucleotide Polymorphism Profiling
Sunghwan Lee, M.D., Yu Jin Park, M.D., Ph.D., Saeam Shin, M.D., Ph.D., Eun-Ki Min, M.D., Yongseop Lee, M.D., Mi Ri Park, B.S., Dongju Won, M.D., Deok-Gie Kim, M.D., Ph.D., Myoung Soo Kim, M.D., Ph.D., Dong Jin Joo, M.D., Ph.D., Jong Rak Choi, M.D., Ph.D., Su Jin Jeong, M.D., Ph.D., Jae Geun Lee, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0068
- 11 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessChimerism Analysis Through Shallow Whole-Genome Sequencing and Single-Nucleotide Polymorphism Profiling
Sunghwan Lee, M.D., Yu Jin Park, M.D., Ph.D., Saeam Shin, M.D., Ph.D., Eun-Ki Min, M.D., Yongseop Lee, M.D., Mi Ri Park, B.S., Dongju Won, M.D., Deok-Gie Kim, M.D., Ph.D., Myoung Soo Kim, M.D., Ph.D., Dong Jin Joo, M.D., Ph.D., Jong Rak Choi, M.D., Ph.D., Su Jin Jeong, M.D., Ph.D., Jae Geun Lee, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0068
- Open Access
- 24 November 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 476-485
Performance Evaluation of Whole-Genome Amplification Platforms for Clinical Next-Generation Sequencing with Minimal Nucleic Acid Input
Namsoo Kim, M.D., Hyeon Ah Lee, Ph.D., Miri Park, B.S., Yehyun Kang, B.S., Dongju Won, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Yu Jin Park, M.D., and Saeam Shin, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0348
- 24 November 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 476-485
Open AccessPerformance Evaluation of Whole-Genome Amplification Platforms for Clinical Next-Generation Sequencing with Minimal Nucleic Acid Input
Namsoo Kim, M.D., Hyeon Ah Lee, Ph.D., Miri Park, B.S., Yehyun Kang, B.S., Dongju Won, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Yu Jin Park, M.D., and Saeam Shin, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0348
- Open Access
- 13 January 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (2) , 199-208
Prognostic Value of Residual Circulating Tumor DNA in Metastatic Pancreatic Ductal Adenocarcinoma
Hongkyung Kim, M.D., Ph.D., Jinho Lee, M.D., Mi Ri Park, B.S., Zisun Choi, M.S., Seung Jung Han, Ph.D., Dongha Kim, M.S., Saeam Shin, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Jong Rak Choi, M.D., Ph.D., and Seung Woo Park, M.D., Ph.D.. Ann Lab Med 2025;45:199-208. https://doi.org/10.3343/alm.2024.0345
- 13 January 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (2) , 199-208
Open AccessPrognostic Value of Residual Circulating Tumor DNA in Metastatic Pancreatic Ductal Adenocarcinoma
Hongkyung Kim, M.D., Ph.D., Jinho Lee, M.D., Mi Ri Park, B.S., Zisun Choi, M.S., Seung Jung Han, Ph.D., Dongha Kim, M.S., Saeam Shin, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Jong Rak Choi, M.D., Ph.D., and Seung Woo Park, M.D., Ph.D.. Ann Lab Med 2025;45:199-208. https://doi.org/10.3343/alm.2024.0345
- Open Access
- 30 September 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (1) , 90-95
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Mi Ri Park, B.S., Bon Park, B.S., Kyung Ju Ryu, Ph.D., Sang Eun Yoon, M.D., Ph.D., Won Seog Kim, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0257
- 30 September 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (1) , 90-95
Open AccessFeasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Mi Ri Park, B.S., Bon Park, B.S., Kyung Ju Ryu, Ph.D., Sang Eun Yoon, M.D., Ph.D., Won Seog Kim, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0257
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (28)
Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022
Na B, et al. J Korean Med Sci. 2024 Jun;39:e206. https://doi.org/10.3346/jkms.2024.39.e206
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (28)
Open AccessGenotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022
Na B, et al. J Korean Med Sci. 2024 Jun;39:e206. https://doi.org/10.3346/jkms.2024.39.e206
- Open Access
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 328-336
Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia
Jin Ju Kim, M.D., Ji Eun Jang, M.D., Hyeon Ah Lee, M.S., Mi Ri Park, B.S., Hye Won Kook, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Yoo Hong Min, M.D., Saeam Shin, M.D., and June-Won Cheong, M.D.. Ann Lab Med 2023;43:328-36. https://doi.org/10.3343/alm.2023.43.4.328
- 24 February 2023
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 43 (4) , 328-336
Open AccessDevelopment of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia
Jin Ju Kim, M.D., Ji Eun Jang, M.D., Hyeon Ah Lee, M.S., Mi Ri Park, B.S., Hye Won Kook, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Yoo Hong Min, M.D., Saeam Shin, M.D., and June-Won Cheong, M.D.. Ann Lab Med 2023;43:328-36. https://doi.org/10.3343/alm.2023.43.4.328
- 28 October 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (12) , 1519-1528
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden
Ultra-deep sequencing to detect low-frequency mutations in circulating tumor-derived DNA (ctDNA) increases the diagnostic value of liquid biopsy. The demand for large ctDNA panels for comprehensive genomic profiling and tumor mutational burden (TMB) estimation is increasing; however, few ctDNA panels for TMB have been validated. Here, we designed a ctDNA panel with 531 genes, named TMB500, along with a technical and clinical validation. Synthetic reference cell-free DNA materials with predefined allele frequencies were sequenced in a total of 92 tests in 6 batches to evaluate the precision, linearity, and limit of detection of the assay. We used clinical samples from 50 patients with various cancers, 11 healthy individuals, and paired tissue samples. Molecular barcoding and data analysis were performed using customized pipelines. The assay showed high precision and linearity (coefficient of determination, r2 =0.87) for all single nucleotide variants, with a limit of detection of 0.24%. In clinical samples, the TMB500 ctDNA assay detected most variants present and absent in tissues, showing that ctDNA could assess tumor heterogeneity in different tissues and metastasis sites. The estimated TMBs correlated well between tissue and blood, except in 4 cases with extreme heterogeneity that showed very high blood TMBs compared to tissue TMBs. A pilot evaluation showed that the TMB500 assay could be used for disease monitoring. The TMB500 assay is an accurate and reliable ctDNA assay for many clinical purposes. It may be useful for guiding the treatment of cancers with diverse genomic profiles, estimating TMB in immune therapy, and disease monitoring.
- 28 October 2022
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (12) , 1519-1528
Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden
Ultra-deep sequencing to detect low-frequency mutations in circulating tumor-derived DNA (ctDNA) increases the diagnostic value of liquid biopsy. The demand for large ctDNA panels for comprehensive genomic profiling and tumor mutational burden (TMB) estimation is increasing; however, few ctDNA panels for TMB have been validated. Here, we designed a ctDNA panel with 531 genes, named TMB500, along with a technical and clinical validation. Synthetic reference cell-free DNA materials with predefined allele frequencies were sequenced in a total of 92 tests in 6 batches to evaluate the precision, linearity, and limit of detection of the assay. We used clinical samples from 50 patients with various cancers, 11 healthy individuals, and paired tissue samples. Molecular barcoding and data analysis were performed using customized pipelines. The assay showed high precision and linearity (coefficient of determination, r2 =0.87) for all single nucleotide variants, with a limit of detection of 0.24%. In clinical samples, the TMB500 ctDNA assay detected most variants present and absent in tissues, showing that ctDNA could assess tumor heterogeneity in different tissues and metastasis sites. The estimated TMBs correlated well between tissue and blood, except in 4 cases with extreme heterogeneity that showed very high blood TMBs compared to tissue TMBs. A pilot evaluation showed that the TMB500 assay could be used for disease monitoring. The TMB500 assay is an accurate and reliable ctDNA assay for many clinical purposes. It may be useful for guiding the treatment of cancers with diverse genomic profiles, estimating TMB in immune therapy, and disease monitoring.